Jeremy Willcocks has been recognised by The Legal 500 and Chambers for his M&A and corporate work. According to Chambers UK, he is noted by sources as a "first-class corporate adviser who is commercially aware of a client's needs" (2015) with "an incredible breadth of expertise" (2017) and "always seems to have the client in the forefront of his mind" (2019). The Legal 500 UK has noted that he "leads his team "from the front" and has surrounded himself with very complementary and equally high performing team members" (2021).

Jeremy undertakes a broad range of mergers and acquisitions, corporate finance, and corporate advisory work. He advises on share and asset sales, IPOs, public takeovers, shareholder disputes, and joint ventures. Jeremy also has extensive experience with debt capital markets transactions. His clients include public and private companies, private equity funds, and banks.

Jeremy advises clients from a variety of industries, including the life sciences, leisure, financial services, technology, and transport sectors. He has particular experience in advising on cross-border transactions.


  • Advising Norgine B.V., a leading European specialist pharmaceutical company on its sale of Arc Medical Design Limited to Olympus Corporation.
  • Advising Norgine B.V., a leading European specialist pharmaceutical company on the acquisition by its wholly owned subsidiary, SpePharm A.G., of SETOFILM® in Europe, Australia and New Zealand from Applied Pharma Research s.a.
  • TELUS Corporation on the acquisition of Muddy Boots Software Limited.
  • In-Q-Tel, the independent, strategic venture organisation established by the US government to support the missions of the CIA and the broader US intelligence community, in investment transactions involving early-stage technology companies.
  • Armour Home Electronics Limited on the disposal of its office furniture business, Alphason Designs, to Dorel.
  • Diversis Capital UK Limited, as lead partner, on its recommended cash offer for ServicePower Technologies plc.
  • A leading tobacco company on a late stage investment in a UK clean-tech business.
  • Health Partners International on all aspects of the acquisition of the company by DAI Global Health.
  • GVS S.p.A, on the UK aspects of the acquisition of Kuss Filtration Inc. from Industrial Opportunity Partners.
  • Telus International on the remainder of its purchase of a majority stake in CallPoint.
  • Arrowgrass Capital Partners on its acquisition of Oxygen Finance Limited and Oxygen Finance Americas, Inc.
  • OneView Group plc on its reverse takeover and admission to AIM.
  • UK counsel to Diversis Capital on its acquisition of Caligor Rx.
  • Recordati on its acquisition of Laboratorios Casen Fleet S.L.U.
  • The Lerner family on the recommended cash offer by Reform Acquisitions Limited for Aston Villa plc.
  • Armour Group plc on the disposal of its automotive division to AAMP of America.
  • Worldstrides, Inc., a leading educational tour company, on its acquisition of Casterbridge Tours Limited and Rhapsody Tours Limited.
  • Deutsche Asset Management on the sale of a significant minority stake in Fitness First Limited to funds advised by BC Partners.
  • Kraft Foods UK Limited on the sale of its Bird's Custard, Angel Delight and associated brands to Premier Foods.
  • Veolia Transport UK Limited on the acquisition and disposal of various transport companies including the purchase of Shamrock Travel Limited, the recommended cash offer for Dunn-Line plc, and the sale of Veolia Transport's London bus business to National Express Group plc.
  • The Association of the British Pharmaceutical Industry on its conversion to a company limited by guarantee.
  • Leading pharmaceutical companies on acquisitions, disposals, and shareholder issues.


Chambers UK
Corporate/M&A: Mid-Market (London) (2013-2021)
The Legal 500 UK
Venture Capital (2021)
"Leading Individual" – Finance: Debt Capital Markets (2015-2021)
Finance: Debt Capital Markets (2009-2021)
Corporate/M&A: Mid-Market (2008-2020)
Corporate and Commercial: Venture Capital (2008-2020)
Pharmaceuticals and Biotechnology (2017-2019)
Private Equity: Transactions (2019) Data Protection, Privacy and Cybersecurity (2017)
"Highly Regarded" – Capital Markets: Debt, Equity (UK) (2019-2022)
"Highly Regarded" – Capital Markets: M&A (UK) (2019-2022)
"Notable Practitioner" – Capital Markets: Debt, Equity (UK) (2018)
"Notable Practitioner" – M&A (UK) (2018)


  • LLB, Warwick University, 1987
  • England and Wales

Email Disclaimer